ClinicalTrials.gg
Status unknownNCT04359576TromboFETUpdated Apr 20, 2021

Frozen-thawed Embryo Transfers and Hormone Substitution on Thrombotic Risk Markers

An observational study in Frozen Embryo Transfer, sponsored by Horsens Hospital. Status unknown at 1 site in Denmark. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-04-20.

Sponsored by Horsens Hospital · Observational

How we know

The sponsor has not verified this record recently (last verified Apr 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The study focus on the impact of estrogen/progesterone substitution during artificial cycle frozen embryo transfer (AC-FET) in women undertaking assisted reproductive technology treatment (ART).

Read the detailed description

The aim is to investigate whether the coagulation is activated in women undergoing estrogen/progesterone substitution during artificial cycle frozen embryo transfer (AC-FET) in assisted reproductive technology treatment (ART). An activation of the coagulation might induce an increased thromboembolic risk in these women. Thus, the present study may lead to improvement of the current treatment protocol for women receiving AC-FET and ultimately prevent thromboembolic complications for woman in fertility treatment.

02

Conditions studied

  • Frozen Embryo Transfer
03

In context

Lead sponsor

Horsens Hospital is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Healthy women receiving FET

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women receiving FET with or without estrogen/progesterone substitution

Exclusion criteria

Exclusion Criteria:

  • Known bleeding disorder
  • Indication for thromboprophylaxis during ART treatment
  • Treatment with anti- medication including non--anti-inflammatory drugs (NSAIDs) within the last week
  • Donor recipients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • FET

    Estrogen/progesterone substituted and natural cycles

    Diagnostic Test: Primary and secondary hemostasis

Interventions

  • Diagnostic testPrimary and secondary hemostasis

    Focus on platelet aggregation, primary and secondary hemostasis parameters

06

What researchers measure

Primary outcomes

  1. coagulation

    Primary and secondary hemostasis parameters

    Time frame: 1 year

07

Study locations

1 site
  • Horsens Regional Hospital
    Horsens, 8700, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2019 (actual). Primary completion is estimated for Mar 2022, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2020
First posted
Apr 24, 2020
StartActual
Aug 1, 2019
Primary completionEst.
Mar 2022
CompletionEst.
Dec 2024
Last update
Apr 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04359576
Lead sponsor
Horsens Hospital
Responsible party
Ulla Breth Knudsen (Professor, Horsens Hospital) — Principal investigator
First posted
Apr 24, 2020
Start date
Aug 1, 2019
Primary completion
Mar 2022 (estimated)
Completion
Dec 2024 (estimated)
Last update
Apr 20, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion